Kathryn Mahoney

1. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
   2025/05/23 by Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney +14 · 1 voice · 1 citation
   Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #Pharmacological Receptor Mechanisms and Effects #SARS-CoV-2 and COVID-19 Research